Estradiol and Progesterone Levels Following Frozen Embryo Transfer
NCT ID: NCT04997525
Last Updated: 2025-01-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
305 participants
INTERVENTIONAL
2021-04-20
2024-12-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Association Between Serum E2 and P on the Day of FET and the Pregnancy Outcome
NCT04114500
Frozen-thawed Embryo Transfers and Hormone Substitution on Thrombotic Risk Markers
NCT04359576
Progesterone Supplementation on Women Having Low Progesterone Levels on Transfer Day
NCT04897269
Pregnancy Outcomes of Patients Having NC-FET Regarding the Progesterone Levels
NCT05690360
Effect of Intramuscular Progesterone Supplementation on Clinical and Ongoing Pregnancy Rates in Patients With Low Serum Progesterone Levels on the Day of Embryo Transfer in Artificial Frozen Cycles
NCT04837768
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Included women will undergo blood testing every two weeks for serum estradiol and progesterone levels until gestational age 9+6. Routine vaginal ultrasounds will be performed as well as additional pregnancy ultrasounds.
Secondary obstetric outcomes will be investigated using the womens medical journals.
All the treatments are considered standard treatments for FET.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
HEALTH_SERVICES_RESEARCH
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Natural cycle
These women will follow their natural cycle and receive one injection of hCG for stimulation of ovulation before embryo transfer
Chorionic Gonadotropin, Alpha
In either natural cycle or combined with Follitropin Alfa
Estradiol and progesterone
These women will receive daily estradiol and progesterone tablets/capsules before and after embryo transfer. Treatment will continue until gestational age 9+6
Estradiol Tablets
Combined with progesterone
Progesterone
Combined with estradiol
Gonadotropin
These women will receive daily gonadotropin injection before embryo transfer. Ovulation will be stimulated using hCG injection.
Follitropin Alfa
Combined with hCG
Chorionic Gonadotropin, Alpha
In either natural cycle or combined with Follitropin Alfa
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Estradiol Tablets
Combined with progesterone
Progesterone
Combined with estradiol
Follitropin Alfa
Combined with hCG
Chorionic Gonadotropin, Alpha
In either natural cycle or combined with Follitropin Alfa
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI \< 35 kg/m2
* Normal wet smear within the past three years
* Thawed blastocysts (day 5 or 6) after either IVF or ICSI treatment
Exclusion Criteria
* BMI \> 35 kg/m2
* Oocyte donation
* HIV/ hepatitis
* Undiagnosed vaginal bleeding
* Uterine malformations
* Persisting ovarian cysts
* Tumors in Hypothalamus, pituitary, thyroid or adrenal
* Previous breast cancer
* BRCA1/2
* Unregulated thyroid disease
* Cardiovascular disease
* Breast feeding
* Present or previous chemotherapy/radiation therapy
* Present or previous malignant disease
* Smoking
* Alcohol/drug abuse
18 Years
40 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Copenhagen University Hospital, Hvidovre
OTHER
Copenhagen University Hospital at Herlev
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Pernille Fog Svendsen, DMSc
DMSc
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Herlev University Hospital
Herlev, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020-001218-39
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.